Xiangyun Kong Selected Research

Immune Checkpoint Inhibitors

1/2023

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiangyun Kong Research Topics

Disease

6	Nasopharyngeal Carcinoma 02/2024 - 01/2020
2	Myocardial Infarction 01/2023 - 01/2021
2	Death (Near-Death Experience) 01/2023 - 01/2021
2	Thrombosis (Thrombus) 01/2023 - 01/2021
1	Disease Progression 02/2024
1	Neoplasm Metastasis (Metastasis) 10/2023
1	Non-ST Elevated Myocardial Infarction 01/2023
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023
1	Inflammation (Inflammations) 01/2023
1	Neoplasms (Cancer) 01/2023
1	Acute Coronary Syndrome 08/2022
1	Dysbiosis 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Atrial Fibrillation 01/2021
1	Colitis 10/2014
1	Wounds and Injuries (Trauma) 01/2014
1	Carcinoma (Carcinomatosis) 05/2013

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2021
2	omega-Chloroacetophenone (Mace)IBA 01/2023 - 01/2023
1	3-nitrophenyl 3-piperidinecarboxylate (MNPC)IBA 10/2023
1	camrelizumabIBA 01/2023
1	apatinibIBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	AlbuminsIBA 01/2023
1	C-Reactive ProteinIBA 01/2023
1	AnticoagulantsIBA 01/2021
1	Caspase 9IBA 01/2021
1	Sulfonic AcidsIBA 10/2014
1	17-hydroxyestrane-3-carbonitrile (ECN)IBA 10/2014
1	2-aminoethoxydiphenyl borateIBA 01/2014
1	Messenger RNA (mRNA)IBA 05/2013
1	Proteins (Proteins, Gene)FDA Link 05/2013

Therapy/Procedure

3	Stents 01/2023 - 01/2021
2	Chemoradiotherapy 02/2024 - 01/2020
2	Radiotherapy 02/2024 - 10/2023
2	Therapeutics 02/2024 - 11/2023
2	Drug Therapy (Chemotherapy) 02/2024 - 10/2023
1	Induction Chemotherapy 02/2024
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 02/2024
1	Immunotherapy 11/2023